IFNα activates dormant haematopoietic stem cells in vivo
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Maintenance of the blood system is dependent on dormant haematopoietic stem cells (HSCs) with long-term self-renewal capacity. After injury these cells are induced to proliferate to quickly re-establish homeostasis. The signalling molecules promoting the exit of HSCs out of the dormant stage remain largely unknown. Here we show that in response to treatment of mice with interferon-alpha (IFNalpha), HSCs efficiently exit G(0) and enter an active cell cycle. HSCs respond to IFNalpha treatment by the increased phosphorylation of STAT1 and PKB/Akt (also known as AKT1), the expression of IFNalpha target genes, and the upregulation of stem cell antigen-1 (Sca-1, also known as LY6A). HSCs lacking the IFNalpha/beta receptor (IFNAR), STAT1 (ref. 3) or Sca-1 (ref. 4) are insensitive to IFNalpha stimulation, demonstrating that STAT1 and Sca-1 mediate IFNalpha-induced HSC proliferation. Although dormant HSCs are resistant to the anti-proliferative chemotherapeutic agent 5-fluoro-uracil, HSCs pre-treated (primed) with IFNalpha and thus induced to proliferate are efficiently eliminated by 5-fluoro-uracil exposure in vivo. Conversely, HSCs chronically activated by IFNalpha are functionally compromised and are rapidly out-competed by non-activatable Ifnar(-/-) cells in competitive repopulation assays. Whereas chronic activation of the IFNalpha pathway in HSCs impairs their function, acute IFNalpha treatment promotes the proliferation of dormant HSCs in vivo. These data may help to clarify the so far unexplained clinical effects of IFNalpha on leukaemic cells, and raise the possibility for new applications of type I interferons to target cancer stem cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Chronic pro-inflammatory signaling due to chronic infections or repetitive sterile inflammation, however, has been shown to be detrimental to HSPC self-renewal, promoting loss of quiescence and differentiation [61–65].”
From Clonal hematopoiesis and inflammation – the perpetual cycle (2023) · cites this paper as [63]
In the citing paper
“The isolated effects of individual inflammatory cytokines, including type 1 interferons (IFNa/b) 1-3 , type 2 IFN (IFNg) 4-6 , TNFa 7,8 , and IL-1 9-11 , have been well-documented in mouse hematopoietic development.”
From Type 1 interferon perturbates clonal competition by reshaping human blood development (2026) · cites this paper as [9]
In the citing paper
“multiple different sterile and infection-associated inflammatory stimuli have been shown to provoke primitive hematopoietic stem cells (HSCs) to exit their long-term quiescent state and enter into active proliferation”
From Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging (2022) · cites this paper as Essers et al., 2009
In the citing paper
“The sterile inflammation that it promotes results in a temporarily discrete hematologic response consisting of transient peripheral blood (PB) cytopenias and a parallel increase in proliferation of long-term HSCs (LT-HSCs), all of which return to homeostatic levels within 4 days”
From Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging (2022) · cites this paper as Essers et al., 2009
In the citing paper
“In addition to IL-6, other cytokines such as IFNα, IFNγ, IL-1α, IL-1β, and TNFα can also directly activate HSCs (Baldridge et al., 2010; Essers et al., 2009; Pietras et al., 2014; Pietras et al., 2016; Sujer, 2014).”
From Inhibition of Inflammatory Signaling in Tet2 Mutant Preleukemic Cells Mitigates Stress-Induced Abnormalities and Clonal Hematopoiesis (2018) · cites this paper as Essers et al., 2009
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Darnell, J. E., Kerr, L. M., & Stark, G. R. (1994) · Science · doi:10.1126/science.8197455 · Cited by 6,080
HOW CELLS RESPOND TO INTERFERONS
Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.227 · Cited by 3,932
Kiel, M. J., Yilmaz, Ö. H., Iwashita, T., Yilmaz, O. H., Terhorst, C., & Morrison, S. J. (2005) · Cell · doi:10.1016/j.cell.2005.05.026 · Cited by 3,168
Functional Role of Type I and Type II Interferons in Antiviral Defense
Müller, U., Steinhoff, U., Reis, L. F. L., Hemmi, S., Pavlovic, J., Zinkernagel, R. M., & Aguet, M. (1994) · Science · doi:10.1126/science.8009221 · Cited by 2,453
Long-Term Lymphohematopoietic Reconstitution by a Single CD34-Low/Negative Hematopoietic Stem Cell
Osawa, M., Hanada, K.-I., Hamada, H., & Nakauchi, H. (1996) · Science · doi:10.1126/science.273.5272.242 · Cited by 2,140
Wilson, A., Laurenti, E., Oser, G., van der Wath, R. C., Blanco-Bose, W., Jaworski, M., Offner, S., Dunant, C. F., Eshkind, L., Bockamp, E., et al. (2008) · Cell · doi:10.1016/j.cell.2008.10.048 · Cited by 1,908
Self-citationInducible Gene Targeting in Mice
Kühn, R., Schwenk, F., Aguet, M., & Rajewsky, K. (1995) · Science · doi:10.1126/science.7660125 · Cited by 1,641
Bone-marrow haematopoietic-stem-cell niches
Wilson, A., & Trumpp, A. (2006) · Nature Reviews Immunology · doi:10.1038/nri1779 · Cited by 1,354
Self-citationHematopoietic Stem Cell Quiescence Maintained by p21 cip1/waf1
Cheng, T., Rodrigues, N., Shen, H., Yang, Y.-G., Dombkowski, D., Sykes, M., & Scadden, D. T. (2000) · Science · doi:10.1126/science.287.5459.1804 · Cited by 1,339
Targeted Disruption of the Mouse Stat1 Gene Results in Compromised Innate Immunity to Viral Disease
Durbin, J. E., Hackenmiller, R., Simon, M. C., & Levy, D. E. (1996) · Cell · doi:10.1016/s0092-8674(00)81289-1 · Cited by 1,242
Cited by
Items 601–700 of 1,002
E4F1 Is a Master Regulator of CHK1-Mediated Functions
Grote, D., Moison, C., Duhamel, S., Chagraoui, J., Girard, S., Yang, J., Mayotte, N., Coulombe, Y., Masson, J., Brown, G. W., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.019 · Cited by 38
“E4f1 Deficiency Results in Cell-Autonomous Hematopoietic Defects The rapid lethality of E4f1mutant primary mice (Figure 1C) along with short-term side effects of pIpC administration (Essers et al., 2009) precluded the analysis of the hematopoietic system as classically performed.”
BackgroundMaier, B. B., Hladik, A., Lakovits, K., Korosec, A., Martins, R., Kral-Pointner, J. B., Mesteri, I., Strobl, B., Müller, M. M., Kalinke, U., et al. (2016) · European Journal of Immunology · doi:10.1002/eji.201546201 · Cited by 35
Self-citationMicrobe-Induced Inflammatory Signals Triggering Acquired Bone Marrow Failure Syndromes
Espinoza, J. L., Kotecha, R. R., & Nakao, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00186 · Cited by 30
ETV2/ER71 regulates hematopoietic regeneration by promoting hematopoietic stem cell proliferation
Xu, C., Lee, T., Sakurai, N., Krchma, K., Liu, F., Li, D., Wang, T., & Choi, K. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20160923 · Cited by 30
“…severe phenotype observed by Lee et al. (2011) could be caused by the combined effect between Etv2 loss and pIpC treatment, which perturbs steady-state hematopoiesis (Essers et al., 2009; Sato et al., 2009), we determined whether Etv2 might have an unexpected role in non–steady-state hematopoiesis.”
BackgroundBalancing STAT Activity as a Therapeutic Strategy
Polak, K. L., Chernosky, N. M., Smigiel, J. M., Tamagno, I., & Jackson, M. W. (2019) · Cancers · doi:10.3390/cancers11111716 · Cited by 31
Navigating the road toward optimal initial therapy for chronic myeloid leukemia
Okimoto, R. A., & Etten, R. A. V. (2011) · Current Opinion in Hematology · doi:10.1097/moh.0b013e32834399a5 · Cited by 29
The Rationale for Immunotherapy in Myeloproliferative Neoplasms
Masárová, L., Bose, P., & Verstovšek, S. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00527-7 · Cited by 29
Visualizing the Selectivity and Dynamics of Interferon Signaling In Vivo
Stifter, S. A., Bhattacharyya, N. D., Sawyer, A. J., Cootes, T. A., Stambas, J., Doyle, S. E., Feigenbaum, L., Paul, W. E., Britton, W. J., Sher, A., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.11.021 · Cited by 31
Wang, W., Zhang, Y., Dettinger, P., Reimann, A., Kull, T., Loeffler, D., Manz, M. G., Lengerke, C., & Schroeder, T. (2021) · Blood · doi:10.1182/blood.2020008386 · Cited by 33
Chen, Y., Zou, J., Cheng, F., & Li, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.769730 · Cited by 32
Immunopathology of chronic critical illness in sepsis survivors: Role of abnormal myelopoiesis
Rincon, J. C., Efron, P. A., & Moldawer, L. L. (2022) · Journal of Leukocyte Biology · doi:10.1002/jlb.4mr0922-690rr · Cited by 34
Influenza A virus infection instructs hematopoiesis to megakaryocyte-lineage output
Rommel, M. G. E., Walz, L., Fotopoulou, F., Kohlscheen, S., Schenk, F., Miskey, C., Botezatu, L., Krebs, Y., Voelker, I. M., Wittwer, K., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111447 · Cited by 31
Self-citationHypercholesterolemia Tunes Hematopoietic Stem/Progenitor Cells for Inflammation and Atherosclerosis
Ma, X., & Feng, Y. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17071162 · Cited by 35
tRNA m1A modification regulate HSC maintenance and self-renewal via mTORC1 signaling
Zuo, H., Wu, A., Wang, M., Hong, L., & Wang, H. (2024) · Nature Communications · doi:10.1038/s41467-024-50110-9 · Cited by 33
Remodeling the tumor dormancy ecosystem to prevent recurrence and metastasis
Liang, Y., Chen, W., Zhang, Y., & Li, L. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02328-2 · Cited by 36
Cell Adhesion Molecules in Normal and Malignant Hematopoiesis: from Bench to Bedside
Lévesque, J.-P., & Winkler, I. G. (2016) · Current Stem Cell Reports · doi:10.1007/s40778-016-0066-0 · Cited by 31
Munz, C. M., Dressel, N., Chen, M., Grinenko, T., Roers, A., & Gerbaulet, A. (2023) · Blood · doi:10.1182/blood.2022018996 · Cited by 43
Nasiri, K., Mohammadzadehsaliani, S., Kheradjoo, H., Shabestari, A. M., Eshaghizadeh, P., Pakmehr, A., Alsaffar, M. F., Al-Naqeeb, B. Z. T., Yasamineh, S., & Gholizadeh, O. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01122-3 · Cited by 29
“For example, using ds-RNA as a viral replication inhibitor led to an HSCs increasing rapidly in an IFNα-receptor-affiliate method [45].”
MethodEssential roles for Pot1b in HSC self-renewal and survival
Wang, Y., Shen, M., & Chang, S. S. (2011) · Blood · doi:10.1182/blood-2011-06-361527 · Cited by 31
Blom-Potar, M. C., Chamond, N., Cosson, A., Jouvion, G., Droin-Bergère, S., Huerre, M., & Minoprio, P. M. C. (2010) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0000793 · Cited by 28
“Rather, the infection induces the expression of Sca-1 in a considerable number of ckit hematopoietic progenitors, possibly resulting from the release of pro-inflammatory cytokines, as postulated [29,31].”
BackgroundCipriani, P., Ruscitti, P., Benedetto, P. D., Carubbi, F., Liakouli, V., Berardicurti, O., Ciccia, F., Triolo, G., & Giacomelli, R. (2015) · Cytotherapy · doi:10.1016/j.jcyt.2014.12.006 · Cited by 29
Integrin αvβ3 enhances the suppressive effect of interferon‐γ on hematopoietic stem cells
Umemoto, T., Matsuzaki, Y., Shiratsuchi, Y., Hashimoto, M., Yoshimoto, T., Nakamura‐Ishizu, A., Petrich, B. G., Yamato, M., & Suda, T. (2017) · The EMBO Journal · doi:10.15252/embj.201796771 · Cited by 30
“Importantly, excess IFN is known to impair the LTR activity of HSCs (Essers et al , 2009; Baldridge et al , 2010; de Bruin et al , 2013; Nakagawa et al , 2015), possibly through the activation of STAT1, a core signaling molecule downstream of IFNs (Darnell et al , 1994).”
The transcription factor NFAT5 limits infection-induced type I interferon responses
Encabo, H. H., Traveset, L., Argilaguet, J. M., Angulo, A., Nistal‐Villán, E., Jaiswal, R., Escalante, C. R., Gekas, C., Meyerhans, A., Aramburu, J. F., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20190449 · Cited by 31
“4 K. Activation of HSCs with IFNα in vivo (24 h) was done by injecting IFNα (100,000 U/mouse; Miltenyi Biotec, Cat#130-093-131) subcutaneously as previously described (Essers et al., 2009).”
BackgroundMethodInfluentialJourney of monocytes and macrophages upon influenza A virus infection
Ruscitti, C., Radermecker, C., & Marichal, T. (2024) · Current Opinion in Virology · doi:10.1016/j.coviro.2024.101409 · Cited by 32
A novel STING variant triggers endothelial toxicity and SAVI disease
Valeri, E., Breggion, S., Barzaghi, F., Alezz, M. A., Crivicich, G., Pagani, I., Forneris, F., Sartirana, C., Costantini, M., Costi, S., et al. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20232167 · Cited by 29
“…shown to lead to increased proliferation and myeloid skewing at the expense of self-renewal ad repopulating capacity in several preclinical models (Essers et al., 2009; Lopez et al., 2022; Dybedal et al., 2001) With the advancement of therapeutic strategies that limit pathology but not…”
Holmes, D. A., Suto, E., Lee, W. P., Ou, Q., Gong, Q., Smith, H. R. C., Caplazi, P., & Chan, A. C. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20142130 · Cited by 28
“However, chronic activation of the IFN pathway results in HSC exhaustion and impairs HSC func tions (Essers et al., 2009).”
BackgroundResultInfluentialShould Biomarkers Be Used to Design Personalized Medicine for the Treatment of Glioblastoma?
Weller, M., Wick, W., Hegi, M. E., Stupp, R., & Tabatabai, G. (2010) · Future Oncology · doi:10.2217/fon.10.113 · Cited by 27
Curing Chronic Myeloid Leukemia
Réa, D., Rousselot, P. H., Guilhot, J., Guilhot, F., & Mahon, F. (2012) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-012-0117-2 · Cited by 27
The Elusive Chronic Myeloid Leukemia Stem Cell: Does It Matter and How Do We Eliminate It?
Carter, B. Z., Mak, D. H. F., Cortes, J. E., & Andreeff, M. (2010) · Seminars in Hematology · doi:10.1053/j.seminhematol.2010.06.006 · Cited by 30
Kreil, S., Waghorn, K., Ernst, T., Chase, A., White, H., Hehlmann, R., Reiter, A., Hochhaus, A., Cross, N. C. P., & on behalf of the German CML Study Group (2010) · Haematologica · doi:10.3324/haematol.2009.011510 · Cited by 27
Targeting Glioma Stem Cells: Therapeutic Opportunities and Challenges
Mahdi, A., Aittaleb, M., & Tissir, F. (2025) · Cells · doi:10.3390/cells14090675 · Cited by 28
“Along this line, therapy resistant and dormant hematopoietic stem cells were successfully activated upon treatment with IFN α and then eliminated using 5-fluorouracil (5-FU) [215].”
Nanocarrier-mediated drugs targeting cancer stem cells: an emerging delivery approach
Malhi, S. S., & Gu, X. (2015) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2015.998648 · Cited by 27
Bioconjugation strategies and clinical implications of Interferon-bioconjugates
Hauptstein, N., Meinel, L., & Lühmann, T. C. (2022) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2022.02.006 · Cited by 26
Darroch, H., Keerthisinghe, P., Sung, Y. J., Rolland, L., Prankerd-Gough, A., Crosier, P. S., Astin, J. W., & Hall, C. J. (2023) · Science Advances · doi:10.1126/sciadv.adf9904 · Cited by 27
Diversification of dendritic cell subsets: Emerging roles for STAT proteins
Li, H. S., & Watowich, S. S. (2013) · JAK-STAT · doi:10.4161/jkst.25112 · Cited by 30
The long non-coding RNA Meg3 is dispensable for hematopoietic stem cells
Sommerkamp, P., Renders, S., Ladel, L., Hotz‐Wagenblatt, A., Schönberger, K., Zeisberger, P., Przybylla, A., Sohn, M., Zhou, Y., Klibanski, A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-38605-8 · Cited by 28
Self-citationKaplan, I. M., Morisot, S., Heiser, D., Cheng, W., Kim, M. J., & Civin, C. I. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002806 · Cited by 26
Hematopoietic stem and progenitor cells as a reservoir for trained immunity
Tran, B. T., Jeyanathan, V., Cao, R., Kaufmann, E., & King, K. Y. (2025) · eLife · doi:10.7554/elife.106610 · Cited by 28
Targeting the Microenvironment in MDS: The Final Frontier
Teodorescu, P., Paşca, S., Dima, D. M., Tomuleasa, C., & Ghiaur, G. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01044 · Cited by 26
“RNA-seq data suggests that treatment with 5-Aza optimizes interferon signaling and extracellularmatrix homeostasis, including collagen type IV and VI with major implications for HSC anchorage, self-renewal, and differentiation (Essers et al., 2009; Gattazzo et al., 2014; Wenk et al., 2018).”
MethodATF3 Prevents Stress-Induced Hematopoietic Stem Cell Exhaustion
Liu, Y., Chen, Y., Deng, X., & Zhou, J. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.585771 · Cited by 26
“Under hematopoietic stress conditions such as infections, chemotherapy, or transplantation, HSCs exit quiescence, rapidly proliferate, and differentiate into mature cells to replenish blood cell numbers through hematopoiesis (Essers et al., 2009; Baldridge et al., 2010).”
BackgroundTung, L. T., Wang, H., Belle, J. I., Petrov, J. C., Langlais, D., & Nijnik, A. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04202-9 · Cited by 27
DRAG in situ barcoding reveals an increased number of HSPCs contributing to myelopoiesis with age
Urbanus, J. H. M., Cosgrove, J., Beltman, J. B., Elhanati, Y., Moral, R. D. A., Conrad, C., van Heijst, J. W. J., Tubeuf, E., Velds, A., Kok, L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37167-8 · Cited by 29
Saran, S., Tran, D. D. H., Klebba-Färber, S., Losada, P. M., Wiehlmann, L., Koch, A., Chopra, H., Pabst, O., Hoffmann, A., Klopfleisch, R., et al. (2013) · BMC Cell Biology · doi:10.1186/1471-2121-14-51 · Cited by 28
“However, since interferon is one of the important cytokines for hematopoiesis [20], the observed phenotype may be due to the synergistic effects of interferon and knockdown of THOC5.”
BackgroundTelomere, DNA damage, and oxidative stress in stem cell aging
Zhang, J., & Ju, Z. (2010) · Birth Defects Research Part C Embryo Today Reviews · doi:10.1002/bdrc.20190 · Cited by 29
Li, Q., Yang, Z., Zhang, P., Zhao, Y., Yu, X., Xue, P., Shao, Y., Li, Q., Jia, X., Zhang, Q., et al. (2018) · Toxicology Letters · doi:10.1016/j.toxlet.2018.05.037 · Cited by 26
Iriguchi, S., Kikuchi, N., Kaneko, S., Noguchi, E., Morishima, Y., Matsuyama, M., Yoh, K., Takahashi, S., Nakauchi, H., & Ishii, Y. (2014) · Blood · doi:10.1182/blood-2014-05-575225 · Cited by 25
ZHANG, C., Lin, J., Cui, J., Li, B., Cong, L. I. U., Wang, J., Gao, F., & Cai, J. (2011) · Journal of Radiation Research · doi:10.1269/jrr.10098 · Cited by 25
Type I Interferons Promote Severe Disease in a Mouse Model of Lethal Ehrlichiosis
Zhang, Y., Thai, V., McCabe, A. F., Jones, M., & MacNamara, K. C. (2014) · Infection and Immunity · doi:10.1128/iai.01564-13 · Cited by 27
Shi, W., Vu, T., Boucher, D., Pardo, B., Nde, J., PANDITA, R. K., Straube, J., Boyle, G. M., Al‐Ejeh, F., Nag, P., et al. (2017) · Blood · doi:10.1182/blood-2016-06-725093 · Cited by 27
Kaschutnig, P., Bogeska, R., Walter, D., Lier, A., Huntscha, S., & Milsom, M. D. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1068474 · Cited by 26
Cellular and Molecular Mechanisms of Innate Memory Responses
Mhlanga, M. M., Fanucchi, S., Ozturk, M., & Divangahi, M. (2025) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101721-035114 · Cited by 29
Nandy, S., Gangwani, L., Nahleh, Z. A., Subramani, R., Arumugam, A., de la Rosa, J. M., & Lakshmanaswamy, R. (2015) · Future Oncology · doi:10.2217/fon.14.301 · Cited by 25
Mack, R. M., Zhang, L., Breslin, S. P., & Zhang, J. (2021) · Stem Cell Reviews and Reports · doi:10.1007/s12015-021-10230-x · Cited by 26
Gerosa, R. C., Boettcher, S., Kovtonyuk, L. V., Hausmann, A., Hardt, W., Hidalgo, J., Nombela‐Arrieta, C., & Manz, M. G. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005531 · Cited by 25
Epigenetic reversal of hematopoietic stem cell aging in Phf6-knockout mice
Wendorff, A. A., Quinn, S. A., Álvarez, S., Brown, J. A., Biswas, M., Gunning, T. S., Palomero, T., & Ferrando, A. A. (2022) · Nature Aging · doi:10.1038/s43587-022-00304-x · Cited by 24
FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia
Zhu, X., Wei, Y.-S., Yang, Q., Liu, H.-R., Zhi, Z., Zhu, D., Li, X., Hong, D., Yu, Y., & Chen, G. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01400-0 · Cited by 26
Chavez, F. H., Luo, H., Cifani, P., Pine, A., Chu, E. L., Joshi, S., Barin, E., Schurer, A., Chan, M., Chang, K., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38001-x · Cited by 25
Activation of STAT1 is required for interferon-alpha-mediated cell death
Arulampalam, V., Kolosenko, I., Hjortsberg, L., Björklund, A.-C., Grandér, D., & Tamm, K. P. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.10.002 · Cited by 27
Vizirianakis, I. S., Chatzopoulou, M., Bonovolias, I. D., Nicolaou, I., Demopoulos, V. J., & Tsiftsoglou, A. S. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100189a · Cited by 28
Roy, H. B., Zuliani, T., Wolowczuk, I., Faivre, N., Jouy, N., Masselot, B., Kerkaert, J. P., Formstecher, P., & Polakowska, R. R. (2009) · Stem Cells and Development · doi:10.1089/scd.2009.0150 · Cited by 26
Carnevalli, L. S., Scognamiglio, R., Cabezas‐Wallscheid, N., Rahmig, S., Laurenti, E., Masuda, K., Joeckel, L. T., Kuck, A., Sujer, S., Polykratis, A., et al. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20131072 · Cited by 26
“During homeostasis the most primitive HSCs reside in a dormant state while the majority of HSCs are slowly cycling (Sudo et al., 2000; Wilson et al., 2008; Foudi et al., 2009; Trumpp et al., 2010).”
BackgroundSelf-citationHuang, X. F., Nandakumar, V., Tumurkhuu, G., Wang, T., Jiang, X., Hong, B., Jones, L. E., Won, H.-J., Yoshii, H., Ozato, K., et al. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.162 · Cited by 24
Induction of p53 suppresses chronic myeloid leukemia
Peterson, L. F., Lo, M., Liu, Y., Giannola, D. M., Mitrikeska, E., Donato, N. J., Johnson, C. N., Wang, S., Mercer, J., & Talpaz, M. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1272682 · Cited by 25
Ramakrishna, C., & Cantin, E. M. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1006822 · Cited by 27
C/EBPβ is a critical mediator of IFN-α–induced exhaustion of chronic myeloid leukemia stem cells
Yokota, A., Hirai, H., Sato, R., Adachi, H., Sato, F., Hayashi, Y., Satō, A., Kamio, N., Miura, Y., Nakano, M., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018020503 · Cited by 26
Henden, A. S., Varelias, A., Leach, J., Sturgeon, E., Avery, J., Kelly, J., Olver, S. D., Samson, L. D., Härtel, G., Durrant, S., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000453 · Cited by 24
Olofsen, P. A., Fátrai, S., van Strien, P. M. H., Obenauer, J. C., de Looper, H. W. J., Hoogenboezem, R. M., Erpelinck-Verschueren, C. A. J., Vermeulen, M., Roovers, O., Haferlach, T., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100074 · Cited by 25
Novel Combination Treatments Targeting Chronic Myeloid Leukemia Stem Cells
Baghdadi, T. A., Abonour, R., & Boswell, H. S. (2011) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2011.10.003 · Cited by 27
Winkler, I. G., Wiercinska, E., Barbier, V., Nowlan, B., Bonig, H. B., & Lévesque, J.-P. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.01.001 · Cited by 25
Thivakaran, A., Botezatu, L., Hönes, J. M., Schütte, J., Vaßen, L., Al-Matary, Y. S., Patnana, P. K., Zeller, A. C., Heuser, M., Thol, F. R., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.167288 · Cited by 28
Interferon Alfa in the Treatment of Philadelphia-Negative Chronic Myeloproliferative Neoplasms
Hasselbalch, H. C., Kiladjian, J., & Silver, R. T. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6238 · Cited by 24
Txnip Enhances Fitness of Dnmt3a -Mutant Hematopoietic Stem Cells via p21
Zhang, C. R., Ostrander, E. L., Kukhar, O., Mallaney, C., Sun, J., Haussler, E., Celik, H., Koh, W. K., King, K. Y., Gontarz, P., et al. (2022) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0132 · Cited by 23
Sobrino, S., Joseph, L., Magrin, E., Chalumeau, A., Hebert, N., Corsia, A., Denis, A., Roudaut, C., Aussel, C., Leblanc, O., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58321-4 · Cited by 25
Rosenblatt‐Velin, N., Ogay, S., Felley, A., Stanford, W. L., & Pedrazzini, T. (2011) · The FASEB Journal · doi:10.1096/fj.11-189605 · Cited by 26
Concise Review: Modulating Cancer Immunity with Hematopoietic Stem and Progenitor Cells
Wildes, T. J., Flores, C. T., & Mitchell, D. A. (2018) · Stem Cells · doi:10.1002/stem.2933 · Cited by 23
Symmetric and asymmetric activation of hematopoietic stem cells
Loeffler, D., & Schroeder, T. (2021) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000644 · Cited by 26
Sezaki, M., Hayashi, Y., Nakato, G., Wang, Y., Nakata, S., Biswas, S., Morishima, T., Fakruddin, M., Moon, J., Ahn, S., et al. (2022) · The EMBO Journal · doi:10.15252/embj.2022110712 · Cited by 23
Luis, T. C., Barkas, N., Carrelha, J., Giustacchini, A., Mazzi, S., Norfo, R., Wu, B., Aliouat, A., Guerrero, J. A., Rodríguez-Meira, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41691-y · Cited by 26
Barbui, T., Carobbio, A., Stefano, V. D., Álvarez‐Larrán, A., Ghirardi, A., Carioli, G., Fenili, F., Rossi, E., Ciceri, F., Bonifacio, M., et al. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05577-9 · Cited by 23
CD38 promotes hematopoietic stem cell dormancy
Ibneeva, L., Singh, S. P., Sinha, A. N., Eski, S. E., Wehner, R., Rupp, L., Kovtun, I., Pérez-Valencia, J. A., Gerbaulet, A., Reinhardt, S., et al. (2024) · PLoS Biology · doi:10.1371/journal.pbio.3002517 · Cited by 23
Riewaldt, J., Düber, S., Boernert, M., Krey, M., Dembiński, M., Weiß, S., Garbe, A. I., & Kretschmer, K. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00141 · Cited by 24
“Data are representative of at least three independent experiments. of type 1 interferons (IFN-α4, IFN-non-α4, and IFN-β) was found to be moderately increased in liver and LNs of Sf mice (Figure 2F, bottom).”
BackgroundInfluentialSekulovic, S., Gasparetto, M., Lecault, V., Hoesli, C. A., Kent, D. G., Rosten, P., Wan, A., Brookes, C., Hansen, C. L., Piret, J. M., et al. (2011) · Blood · doi:10.1182/blood-2011-04-350066 · Cited by 23
Wang, W., Fujii, H., Kim, H. J., Hermans, K. G., Usenko, T. S., Xie, S. Z.-J., Luo, Z., Ma, J., Celso, C. L., Dick, J. E., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag3214 · Cited by 24
Ramasz, B., Krüger, A., Reinhardt, J., Sinha, A. N., Gerlach, M., Gerbaulet, A., Reinhardt, S., Dahl, A., Chavakis, T., Wielockx, B., et al. (2019) · Blood · doi:10.1182/blood.2019000721 · Cited by 27
Desai, A. B., Qing, Y., & Gerson, S. L. (2013) · Stem Cells · doi:10.1002/stem.1596 · Cited by 25
Escobar, G., Gentner, B., Naldini, L., & Mazzieri, R. (2014) · OncoImmunology · doi:10.4161/onci.28696 · Cited by 26
Mikkola, H. K. A., Radu, C. G., & Witte, O. N. (2010) · Nature Biotechnology · doi:10.1038/nbt0310-237 · Cited by 23
Interferon in chronic myeloid leukaemia: past and future
Guilhot, F., Roy, L., Saulnier, P., & Guilhot, J. (2009) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2009.10.005 · Cited by 24
Replication stress in hematopoietic stem cells in mouse and man
Flach, J., & Milyavsky, M. (2017) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2017.10.001 · Cited by 23
PTEN in Regulating Hematopoiesis and Leukemogenesis
Wu, Y., Zhu, H., & Wu, H. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a036244 · Cited by 22
Pten Cell Autonomously Modulates the Hematopoietic Stem Cell Response to Inflammatory Cytokines
Porter, S. N., Cluster, A. S., Signer, R. A. J., Voigtmann, J., Monlish, D. A., Schuettpelz, L. G., & Magee, J. A. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.04.008 · Cited by 22
“…and supports hematopoiesis, but sustained proliferation impairs HSC function and reduces long-term self-renewal capacity (Baldridge et al., 2010; Essers et al., 2009; Kharas et al., 2010; Rodriguez et al., 2009; Schuettpelz et al., 2014; Van Meter et al., 2007; Yilmaz et al., 2006; Zhang et…”
BackgroundMethodResultInfluentialThe role of immune cells settled in the bone marrow on adult hematopoietic stem cells
Xu, H., Li, Y., & Gao, Y. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05445-3 · Cited by 28
Kolibaba, K. S., Sterchele, J. A., Joshi, A. D., Forsyth, M., Alwon, E., Beygi, H., & Kennealey, G. T. (2013) · Therapeutic Advances in Hematology · doi:10.1177/2040620713478629 · Cited by 23
Hematopoietic Stem Cells in Wound Healing Response
Urao, N., Liu, J., Takahashi, K., & Ganesh, G. (2022) · Advances in Wound Care · doi:10.1089/wound.2021.0065 · Cited by 27
Mian, S. A., & Bonnet, D. A. (2021) · Cancers · doi:10.3390/cancers13164116 · Cited by 25
Polívková, V., Rohoň, P., Klamová, H., Černá, O., Divoká, M., Čuřík, N., Zach, J., Novák, M., Marinov, I., Soverini, S., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155959 · Cited by 22
Vainieri, M. L., Blagborough, A. M., MacLean, A. L., Haltalli, M. L. R., Ruivo, N., Fletcher, H. A., Stumpf, M. P. H., Sinden, R. E., & Celso, C. L. (2016) · Open Biology · doi:10.1098/rsob.160038 · Cited by 22
Trus, I., Udenze, D., Cox, B., Berube, N., Nordquist, R. E., van der Staay, F. J., Huang, Y., Kobinger, G., Safronetz, D., Gerdts, V., et al. (2019) · PLoS Pathogens · doi:10.1371/journal.ppat.1008038 · Cited by 23
“We also suggest studying hematopoietic stem cells in affected fetuses and offspring since excessive IFN-α may impact proliferation and reconstituting ability in hematopoietic stem cells and stem cell niche [83] [84] [85] .”
BackgroundBisht, K., McGirr, C., Lee, S.-Y., Tseng, H., Fleming, W., Alexander, K. A., Matsumoto, T., Barbier, V., Sims, N. A., Müller‐Newen, G., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01413-z · Cited by 26
Melvan, J. N., Siggins, R. W., Bagby, G. J., Stanford, W. L., Welsh, D. A., Nelson, S., & Zhang, P. (2011) · Critical Care Medicine · doi:10.1097/ccm.0b013e31821e89dc · Cited by 22
Metadata
- Authors
- Essers, M. A. G., Offner, S., Blanco-Bose, W. E., Waibler, Z., Kalinke, U., Duchosal, M. A., & Trumpp, A.
- Affiliations
- German Cancer Research Center (DE)
- École Polytechnique Fédérale de Lausanne (CH)
- Paul Ehrlich Institut (DE)
- Center for Experimental and Clinical Infection Research (DE)
- Centre Hospitalier Universitaire Vaudois (CH)
- Corresponding author
- Trumpp, Andreas
- Venue
- Nature
- Published
- 2009-02-11
- Volume
- 458
- Issue
- 7240
- Pages
- 904-908
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2011059916
- Cited by
- 1,368
- References
- 31
- Citations by year
- 2026: 59 · 2025: 72 · 2024: 67 · 2023: 96 · 2022: 91 · 2021: 99 · 2020: 90 · 2019: 72 · 2018: 68 · 2017: 81 · 2016: 82 · 2015: 60 · 2014: 99 · 2013: 80 · 2012: 71
- FWCI
- 56.02
- Type
- journal article
- Language
- en
- Open access
- green
- infoscience.epfl.ch
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion)
- Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Keywords
- hematopoietic stem cells, interferon-alpha, HSC proliferation, STAT1, Sca-1, IFNAR, type I interferon, 5-fluorouracil, leukemia, cancer stem cells, chemosensitization
- MeSH terms
- Animals, Antigens, Ly, Cell Count, Cell Cycle, Fluorouracil, Hematopoietic Stem Cells, Membrane Proteins, Mice, Inbred C57BL, Phosphorylation, Signal Transduction, Up-Regulation, Interferon-alpha, Cell Proliferation, STAT1 Transcription Factor, Mice, Receptor, Interferon alpha-beta
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.